MedImmune,a subsidiary of British Pharmaceutical holding company Astra Zeneca,is embarked on a substantial building program.Best known for its nasal vaccine FluMist,the firm,which employs 3100 people,has broken ground for a 300,000 square foot research facility at its Gaithersburg,Maryland headquarters.At the same time,it bought a second building with 56,000 square feet nearby,and is erecting a 355,000 square foot manufacturing plant in Frederick,Maryland,where it plans to make its pediatric respiratory drug,Synagis.MedImmune comprises 25% of Astra Zeneca's biotech business.
MedImmune is developing a nasal vaccine for the H1N1 virus,or swine flu.The contractor that makes its nasal delivery systems,however,was caught off guard by the new program,and is having trouble meeting the demand for H1N1 devices.The U.S. government has ordered at least 90 miilion dollars' worth of the H1N1 mist,in addition to normal FluMist,which MedImmune has already begun shipping.This year,regular FluMist will be administered as early as August,when many school check-ups are given.
No comments:
Post a Comment